{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:56:33Z","timestamp":1781754993240,"version":"3.54.5"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA056880"],"award-info":[{"award-number":["UG3DA056880"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA055695"],"award-info":[{"award-number":["K23DA055695"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Addictive Behaviors"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.addbeh.2026.108603","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:42:52Z","timestamp":1767685372000},"page":"108603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Risk of opioid overdose during buprenorphine treatment for opioid use disorder in the fentanyl era"],"prefix":"10.1016","volume":"175","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1802-6578","authenticated-orcid":false,"given":"Laura C.","family":"Chambers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Hallowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-4570","authenticated-orcid":false,"given":"Andrew R.","family":"Zullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McClaren","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0604-5595","authenticated-orcid":false,"given":"Marzan A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9051-4798","authenticated-orcid":false,"given":"Rachel","family":"Gaither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macy","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel S.","family":"Wightman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0462-019X","authenticated-orcid":false,"given":"Francesca L.","family":"Beaudoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addbeh.2026.108603_b0005","unstructured":"United States Drug Enforcement Administration. Department of Justice and DEA Announce Seizures of Historic Amounts of Deadly Fentanyl-Laced Fake Pills in Public Safety Surge to Protect US Communities. 2021. Available at: https:\/\/www.dea.gov\/press-releases\/2021\/09\/30\/department-justice-and-dea-announce-seizures-historic-amounts-deadly-0."},{"issue":"12","key":"10.1016\/j.addbeh.2026.108603_b0010","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/add.16318","article-title":"Charting the fourth wave: Geographic, temporal, race\/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021","volume":"118","author":"Friedman","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.addbeh.2026.108603_b0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","article-title":"Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort","volume":"200","author":"Morgan","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.addbeh.2026.108603_b0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/pharma1030010","article-title":"Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and death among Insured patients with Opioid Use Disorder in the United States","volume":"1","author":"Sun","year":"2022","journal-title":"Pharmacoepidemiology"},{"key":"10.1016\/j.addbeh.2026.108603_b0025","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.addbeh.2026.108603_b0030","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.addbeh.2026.108603_b0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for Opioid Use Disorder after Nonfatal Opioid Overdose and Association with Mortality: A Cohort Study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1016\/j.addbeh.2026.108603_b0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.addbeh.2026.108603_b0045","article-title":"Non-fatal overdose risk during and after opioid agonist treatment: A primary care cohort study with linked hospitalisation and mortality records","volume":"22","author":"Domzaridou","year":"2022","journal-title":"Lancet Reg Health Eur."},{"issue":"7","key":"10.1016\/j.addbeh.2026.108603_b0050","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1176\/appi.ajp.2020.20081174","article-title":"Association between Benzodiazepine or Z-Drug Prescriptions and Drug-Related Poisonings among patients Receiving Buprenorphine Maintenance: A Case-Crossover Analysis","volume":"178","author":"Xu","year":"2021","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.addbeh.2026.108603_b0055","article-title":"Quantifying a potential protective effect of buprenorphine on fatality risk during acute fentanyl exposures","volume":"158","author":"Dai","year":"2024","journal-title":"J Subst Use Addict Treat."},{"key":"10.1016\/j.addbeh.2026.108603_b0060","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13(625):eaaz3140","author":"Gillis","year":"2020","journal-title":"Science Signaling"},{"issue":"4","key":"10.1016\/j.addbeh.2026.108603_b0065","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1124\/mol.110.066613","article-title":"\u03bc-opioid receptors: Correlation of agonist efficacy for signalling with ability to activate internalization","volume":"78","author":"McPherson","year":"2010","journal-title":"Molecular Pharmacology"},{"issue":"5","key":"10.1016\/j.addbeh.2026.108603_b0070","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/add.14522","article-title":"What should clinicians do as fentanyl replaces heroin?","volume":"114","author":"Bisaga","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.addbeh.2026.108603_b0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"\u201cEverything is not right anymore\u201d: Buprenorphine experiences in an era of illicit fentanyl","volume":"74","author":"Silverstein","year":"2019","journal-title":"The International Journal on Drug Policy"},{"issue":"2","key":"10.1016\/j.addbeh.2026.108603_b0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/dar.13017","article-title":"High-dose buprenorphine for treatment of high potency opioid use disorder","volume":"39","author":"Danilewitz","year":"2020","journal-title":"Drug and Alcohol Review"},{"issue":"2","key":"10.1016\/j.addbeh.2026.108603_b0085","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/fampra\/cmac098","article-title":"To use or not to use buprenorphine for illegally manufactured fentanyl","volume":"40","author":"Jain","year":"2023","journal-title":"Family Practice"},{"issue":"4","key":"10.1016\/j.addbeh.2026.108603_b0090","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ajad.12869","article-title":"Rapid micro-induction of buprenorphine\/naloxone for opioid use disorder in an inpatient setting: A case series","volume":"28","author":"Klaire","year":"2019","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.addbeh.2026.108603_b0095","series-title":"Poster presentation at the American Society of Addiction Medicine Annual Conference (held virtually)","article-title":"Buprenorphine Macro-Dosing Induction for OUD in the Inpatient setting: A Case Series","author":"Monteiro","year":"2021"},{"issue":"5","key":"10.1016\/j.addbeh.2026.108603_b0100","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1097\/ADM.0000000000000618","article-title":"Rapid transition from Methadone to Buprenorphine Utilizing a Micro-dosing Protocol in the Outpatient Veteran Affairs setting","volume":"14","author":"De Aquino","year":"2020","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.addbeh.2026.108603_b0105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/SAR.S109919","article-title":"Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: The Bernese method","volume":"7","author":"H\u00e4mmig","year":"2016","journal-title":"Substance Abuse and Rehabilitation"},{"issue":"2","key":"10.1016\/j.addbeh.2026.108603_b0110","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/10903127.2020.1747579","article-title":"Buprenorphine Field Initiation of ReScue Treatment by Emergency Medical Services (Bupe FIRST EMS): A Case Series","volume":"25","author":"Carroll","year":"2021","journal-title":"Prehospital Emergency Care"},{"issue":"7","key":"10.1016\/j.addbeh.2026.108603_b0115","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.17128","article-title":"High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder","volume":"4","author":"Herring","year":"2021","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.addbeh.2026.108603_b0120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/JCP.0000000000001308","article-title":"Treatment of Opioid Use Disorder Attributed to Fentanyl with High-Dose Buprenorphine: A Case Report","volume":"41","author":"Baca-Atlas","year":"2021","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"9","key":"10.1016\/j.addbeh.2026.108603_b0125","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine Dose and Time to Discontinuation among patients with Opioid Use Disorder in the Era of Fentanyl","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Network Open"},{"issue":"9","key":"10.1016\/j.addbeh.2026.108603_b0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35478","article-title":"Association of Daily Doses of Buprenorphine with Urgent Health Care utilization","volume":"7","author":"Axeen","year":"2024","journal-title":"JAMA Network Open"},{"issue":"6","key":"10.1016\/j.addbeh.2026.108603_b0135","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/add.70002","article-title":"The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021","volume":"120","author":"Stringfellow","year":"2025","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.addbeh.2026.108603_b0140","article-title":"Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients","volume":"17","author":"Moss","year":"2022","journal-title":"PLoS One1"},{"key":"10.1016\/j.addbeh.2026.108603_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/SAR.S45585","article-title":"New developments in the management of opioid dependence: Focus on sublingual buprenorphine-naloxone","volume":"6","author":"Soyka","year":"2015","journal-title":"Substance Abuse and Rehabilitation"},{"issue":"1\u20132","key":"10.1016\/j.addbeh.2026.108603_b0150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugalcdep.2009.03.020","article-title":"Comparing overdose mortality associated with methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.addbeh.2026.108603_b0155","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/ADM.0000000000001189","article-title":"Evidence on Buprenorphine Dose Limits: A Review","volume":"17","author":"Grande","year":"2023","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.addbeh.2026.108603_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108317","article-title":"Adherence to buprenorphine: An analysis of prescription drug monitoring program data","volume":"216","author":"Pizzicato","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.addbeh.2026.108603_b0165","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.addbeh.2026.108603_b0170","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1176\/ajp.2007.164.5.797","article-title":"A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: A randomized controlled trial","volume":"164","author":"Kakko","year":"2007","journal-title":"The American Journal of Psychiatry"},{"issue":"2 Suppl","key":"10.1016\/j.addbeh.2026.108603_b0175","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","article-title":"Buprenorphine: How to use it right","volume":"70","author":"Johnson","year":"2003","journal-title":"Drug and Alcohol Dependence"},{"issue":"1\u20133","key":"10.1016\/j.addbeh.2026.108603_b0180","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.drugalcdep.2007.10.017","article-title":"Multi-centre observational study of buprenorphine use in 32 italian drug addiction centres","volume":"94","author":"Leonardi","year":"2008","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.addbeh.2026.108603_b0185","unstructured":"United States Food and Drug Administration. Summary Review for Regulatory Action: NDA 22-410 Suboxone (Buprenorphine\/Naloxone) Sublingual Film. 2009. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022410Orig1s000MedR.pdf."},{"issue":"1","key":"10.1016\/j.addbeh.2026.108603_b0190","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/10550887.2011.642758","article-title":"Effect of buprenorphine dose on treatment outcome","volume":"31","author":"Fareed","year":"2012","journal-title":"Journal of Addictive Diseases"},{"issue":"12","key":"10.1016\/j.addbeh.2026.108603_b0195","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/pme.12520","article-title":"Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients","volume":"15","author":"Daitch","year":"2014","journal-title":"Pain Medicine"},{"issue":"2","key":"10.1016\/j.addbeh.2026.108603_b0200","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11414-021-09783-z","article-title":"To Prescribe or not to Prescribe?: Barriers and Motivators for Progressing along each stage of the Buprenorphine Training and Prescribing Path","volume":"50","author":"Winograd","year":"2023","journal-title":"The Journal of Behavioral Health Services & Research"},{"key":"10.1016\/j.addbeh.2026.108603_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103703","article-title":"'Red flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States","volume":"105","author":"Textor","year":"2022","journal-title":"The International Journal on Drug Policy"},{"issue":"14","key":"10.1016\/j.addbeh.2026.108603_b0220","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jama.2024.27976","article-title":"Emergency Clinician Buprenorphine Initiation, subsequent Prescriptions, and Continuous Prescriptions","volume":"333","author":"Dekker","year":"2025","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.addbeh.2026.108603_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108548","article-title":"Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting","volume":"131","author":"Bailey","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.addbeh.2026.108603_b0230","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of Long-Term Buprenorphine Treatment on adverse Health Care Outcomes In Medicaid","volume":"39","author":"Samples","year":"2020","journal-title":"Health Aff (Millwood)."},{"issue":"9","key":"10.1016\/j.addbeh.2026.108603_b0235","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1111\/add.15902","article-title":"Insights from biosurveillance: Non-fatal opioid overdoses in Rhode Island 2019-21","volume":"117","author":"King","year":"2022","journal-title":"Addiction"},{"issue":"16","key":"10.1016\/j.addbeh.2026.108603_b0240","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1001\/jama.2023.1207","article-title":"Trends in Buprenorphine Initiation and Retention in the United States, 2016-2022","volume":"329","author":"Chua","year":"2023","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"10.1016\/j.addbeh.2026.108603_b0245","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamapsychiatry.2022.3673","article-title":"Racial and Ethnic Disparities in Buprenorphine Treatment Duration in the US","volume":"80","author":"Dong","year":"2023","journal-title":"JAMA Psychiatry."},{"issue":"1","key":"10.1016\/j.addbeh.2026.108603_b0250","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/ADM.0000000000000739","article-title":"Retention strategies for Medications for Opioid Use Disorder in adults: A Rapid evidence Review","volume":"15","author":"Chan","year":"2021","journal-title":"Journal of Addiction Medicine"},{"issue":"9","key":"10.1016\/j.addbeh.2026.108603_b0255","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.29677","article-title":"Challenges of estimating the Value of Buprenorphine Injectables","volume":"6","author":"Nelson","year":"2023","journal-title":"JAMA Network Open"},{"issue":"6","key":"10.1016\/j.addbeh.2026.108603_b0260","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.annemergmed.2022.05.032","article-title":"A Neuropharmacological Model to Explain Buprenorphine Induction challenges","volume":"80","author":"Greenwald","year":"2022","journal-title":"Annals of Emergency Medicine"},{"issue":"3","key":"10.1016\/j.addbeh.2026.108603_b0265","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","article-title":"Uniform assessment and ranking of opioid \u03bc receptor binding constants for selected opioid drugs","volume":"59","author":"Volpe","year":"2011","journal-title":"Regulatory Toxicology and Pharmacology"},{"issue":"1","key":"10.1016\/j.addbeh.2026.108603_b0270","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ajad.13069","article-title":"Method for Successfully Inducting individuals who Use Illicit Fentanyl Onto Buprenorphine\/Naloxone","volume":"30","author":"Antoine","year":"2021","journal-title":"The American Journal on Addictions"},{"issue":"8","key":"10.1016\/j.addbeh.2026.108603_b0275","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-098439","article-title":"Comparative effectiveness of maintenance doses of opioid agonist treatment among individuals with opioid use disorder: A target trial emulation protocol using a population-based observational study","volume":"15","author":"Zanette","year":"2025","journal-title":"BMJ Open"}],"container-title":["Addictive Behaviors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460326000109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460326000109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:47:53Z","timestamp":1781754473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306460326000109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":53,"alternative-id":["S0306460326000109"],"URL":"https:\/\/doi.org\/10.1016\/j.addbeh.2026.108603","relation":{},"ISSN":["0306-4603"],"issn-type":[{"value":"0306-4603","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of opioid overdose during buprenorphine treatment for opioid use disorder in the fentanyl era","name":"articletitle","label":"Article Title"},{"value":"Addictive Behaviors","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addbeh.2026.108603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108603"}}